1. Academic Validation
  2. Discovery of biarylaminoquinazolines as novel tubulin polymerization inhibitors

Discovery of biarylaminoquinazolines as novel tubulin polymerization inhibitors

  • J Med Chem. 2014 Jun 12;57(11):4598-4605. doi: 10.1021/jm500034j.
Giovanni Marzaro # 1 Antonio Coluccia # 2 Alessandro Ferrarese 1 Paola Brun 3 Ignazio Castagliuolo 3 Maria Teresa Conconi 1 Giuseppe La Regina 2 Ruoli Bai 4 Romano Silvestri 2 Ernest Hamel 4 Adriana Chilin 1
Affiliations

Affiliations

  • 1 Dipartimento di Scienze del Farmaco, Universitá degli Studi di Padova, via Marzolo 5, 35131 Padova, Italy.
  • 2 Dipartimento di Chimica e Tecnologie del Farmaco, Istituto Pasteur-Fondazione Cenci Bolognetti, Sapienza Universitá di Roma, Piazzale Aldo Moro 5, I-00185 Roma, Italy.
  • 3 Department of Molecular Medicine, University of Padova, via Gabelli 63, 35121 Padova, Italy.
  • 4 Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States.
  • # Contributed equally.
Abstract

Cell cycle experiments with our previously reported 4-biphenylaminoquinazoline (1-3) multityrosine kinase inhibitors revealed an activity profile resembling that of known tubulin polymerization inhibitors. Novel 4-biarylaminoquinazoline analogues of compound 2 were synthesized and evaluated as inhibitors of several tyrosine kinases and of tubulin. Although compounds 1-3 acted as dual inhibitors, the heterobiaryl analogues possessed only anti-tubulin properties and targeted the colchicine site. Furthermore, molecular modeling studies allowed the rationalization of the pharmacodynamic properties of the compounds.

Figures
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验,部分功能也使用 Cookies 帮助我们更好地理解您的需求,为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问,请阅读我们的《隐私声明》